Farnesyltransferase inhibition overcomes oncogene-addicted non-small cell lung cancer adaptive resistance to targeted therapies
Open Access
- 27 June 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Abstract
Drug-tolerance has emerged as one of the major non-genetic adaptive processes driving resistance to targeted therapy (TT) in non-small cell lung cancer (NSCLC). However, the kinetics and sequence of molecular events governing this adaptive response remain poorly understood. Here, we combine real-time monitoring of the cell-cycle dynamics and single-cell RNA sequencing in a broad panel of oncogenic addiction such as EGFR-, ALK-, BRAF- and KRAS-mutant NSCLC, treated with their corresponding TT. We identify a common path of drug adaptation, which invariably involves alveolar type 1 (AT1) differentiation and Rho-associated protein kinase (ROCK)-mediated cytoskeletal remodeling. We also isolate and characterize a rare population of early escapers, which represent the earliest resistance-initiating cells that emerge in the first hours of treatment from the AT1-like population. A phenotypic drug screen identify farnesyltransferase inhibitors (FTI) such as tipifarnib as the most effective drugs in preventing relapse to TT in vitro and in vivo in several models of oncogenic addiction, which is confirmed by genetic depletion of the farnesyltransferase. These findings pave the way for the development of treatments combining TT and FTI to effectively prevent tumor relapse in oncogene-addicted NSCLC patients.Keywords
Funding Information
- Fondation ARC pour la Recherche sur le Cancer (PJA2)
- Fondation pour la Recherche Médicale (DEQ20170839117, DEQ20170839117, DEQ20170839117)
- Institut National de la Santé et de la Recherche Médicale (Inserm, Inserm)
- Fondation Toulouse Cancer Santé (FTCS), Labex TOUCAN, ALK+ &ROS1 France patient association (donation), Kura Oncology
- Institut National Du Cancer (PRT-K18-048)
- Ligue Contre le Cancer (LNCC)
This publication has 81 references indexed in Scilit:
- Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosisCancer Cell, 2021
- Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy ResistanceCancer Cell, 2020
- Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic PathwayCancer Cell, 2020
- Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancerBiochemical Pharmacology, 2019
- A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumorsInvestigational New Drugs, 2018
- Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug ExposureCancer Cell, 2017
- NSCLC harboring EGFR exon‐20 insertions after the regulatory C‐helix of kinase domain responds poorly to known EGFR inhibitorsInternational Journal of Cancer, 2016
- Pathophysiological Functions of Rnd 3/ RhoE2015
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLCCancer Cell, 2010
- Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle ProgressionCell, 2008